84 results
8-K
EX-1.1
OGEN
Oragenics Inc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear doctor” letter, or other notice or action
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
from biological sources. Such raw materials are difficult to procure and may be subject to contamination or recall. Access to and supply of sufficient … sufficient quantities of our products for clinical or commercial requirements would be negatively impacted. A material shortage, contamination, recall
424B5
OGEN
Oragenics Inc
27 Feb 24
Prospectus supplement for primary offering
5:04pm
materials are difficult to procure and may be subject to contamination or recall. Access to and supply of sufficient quantities of raw materials which … for clinical or commercial requirements would be negatively impacted. A material shortage, contamination, recall or restriction on the use of certain
8-K
OGEN
Oragenics Inc
16 Jan 24
Other Events
9:10am
candidates are derived from biological sources. Such raw materials are difficult to procure and may be subject to contamination or recall. Access to and supply … , contamination, recall or restriction on the use of certain biologically derived substances or any raw material used in the manufacture of our products could
424B5
548uhh
16 Jan 24
Prospectus supplement for primary offering
9:04am
8-K
EX-2.1
3uvu2qppm01a
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
EX-10.1
ab4ojv
28 Dec 20
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
5:04pm
8-K
66bllc
8 May 20
Regulation FD Disclosure
7:00am
8-K
EX-1.1
h2p0ikz
25 Mar 19
Oragenics Announces Closing of $12.5 Million Underwritten Public Offering
4:32pm
8-K
EX-1.1
8blekc6 bbw8
17 Jul 18
Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering
4:31pm